Sage Therapeutics (NASDAQ:SAGE) Posts Earnings Results, Misses Estimates By $0.17 EPS

Sage Therapeutics (NASDAQ:SAGE) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17), Briefing.com reports. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The business had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. During the same period last year, the company earned ($2.46) EPS. The business’s revenue for the quarter was up 139.4% on a year-over-year basis.

Sage Therapeutics Trading Up 0.8 %

Shares of SAGE traded up $0.11 during midday trading on Friday, reaching $13.69. The stock had a trading volume of 1,485,521 shares, compared to its average volume of 1,034,430. The firm has a 50 day simple moving average of $18.75 and a 200-day simple moving average of $20.68. Sage Therapeutics has a one year low of $10.92 and a one year high of $59.99. The firm has a market cap of $822.91 million, a PE ratio of -1.53 and a beta of 0.86.

Analysts Set New Price Targets

Several research firms have recently weighed in on SAGE. Mizuho dropped their price objective on shares of Sage Therapeutics from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Friday. Royal Bank of Canada decreased their price target on shares of Sage Therapeutics from $26.00 to $15.00 and set a “sector perform” rating on the stock in a research note on Friday. JPMorgan Chase & Co. raised their price objective on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, March 26th. TD Cowen reduced their price objective on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, April 18th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Thursday. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $37.72.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.